OptoIntel
OptoIntel is a healthcare technology company pioneering the use of hyperspectral imaging combined with machine learning to detect early biomarkers of major diseases through non-invasive retinal imaging. Their technology captures detailed spectral data from the retina, enabling AI to identify disease biomarkers invisible to traditional imaging. This approach aims to transform patient care by enabling early detection and intervention in neurodegenerative diseases such as Alzheimer's, Parkinson's, multiple sclerosis, and ALS, as well as expanding to cardiovascular and renal diseases. OptoIntel's platform is scalable, cost-effective, and operator-independent, designed to streamline pharmaceutical innovation by improving patient enrollment and reducing clinical trial costs. Their technology supports earlier diagnosis, potentially slowing disease progression and improving patient outcomes, positioning them as a leader in oculomics and AI-driven medical diagnostics.
OptoIntel
OptoIntel is a healthcare technology company pioneering the use of hyperspectral imaging combined with machine learning to detect early biomarkers of major diseases through non-invasive retinal imaging. Their technology captures detailed spectral data from the retina, enabling AI to identify disease biomarkers invisible to traditional imaging. This approach aims to transform patient care by enabling early detection and intervention in neurodegenerative diseases such as Alzheimer's, Parkinson's, multiple sclerosis, and ALS, as well as expanding to cardiovascular and renal diseases. OptoIntel's platform is scalable, cost-effective, and operator-independent, designed to streamline pharmaceutical innovation by improving patient enrollment and reducing clinical trial costs. Their technology supports earlier diagnosis, potentially slowing disease progression and improving patient outcomes, positioning them as a leader in oculomics and AI-driven medical diagnostics.
TL;DR
Location: Cambridge, MA
Tech: Hyperspectral retinal imaging + machine learning
Focus: Early, non-invasive detection of neurodegenerative and systemic disease biomarkers
Founded: 2023
Funding: Seed round announced May 23, 2025; investor: SparkLabs Taiwan
Company Overview
Problem Domain
Early detection and screening for neurodegenerative and systemic diseases via ophthalmic biomarkers; improving clinical trial recruitment and reducing trial costs.
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
Investor Signal
“Participated in acceleration/seed investment from SparkLabs Taiwan”